Akari Therapeutics, Plc (AKTX) Stock: A Good Pick In The Biotech Sector?


Akari Therapeutics, Plc (AKTX) is working its way for to the top in the market in today’s trading session. The company, focused on the biotech space, is currently trading at $4.81 after climbing 17.80% so far in today’s session. In terms of biotech stocks, there are several aspects that have the ability to lead to price movement in the market. One of the most common is news. Here are the recent stories centered around AKTX:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-14-19 10:06AM What Kind Of Shareholders Own Akari Therapeutics, Plc (NASDAQ:AKTX)?
07:47AM The Daily Biotech Pulse: Arsanis Completes X4 Merger, EC Nod For Roche, Axovant Offering
Mar-13-19 02:35PM These 4 Tech Stocks Are On The Rise On Wednesday (3/13/19)
10:35AM Akari Therapeutics’ stock rockets on massive volume after ‘successful’ pre-IND FDA meeting
08:30AM Positive FDA Meeting Outlines Path Ahead for Akari Therapeuticss Coversin in Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA)

However, any time investors are making a decision to invest, investors should focus on far more than news, especially in the speculative biotech sector. Here’s what’s happening with Akari Therapeutics, Plc.

Recent Trends From AKTX

Although a gain in a single session, like what we’re seeing from Akari Therapeutics, Plc might cause excitement in some investors, that by itself should not be the basis of a decision to, or not to, buy a company’s stock. It is generally a good idea to look at trends experienced by the stock just a single trading day. As it relates to AKTX, below are the trends that investors have experienced:

  • Past 5 Trading Sessions – Throughout the last 7 days, AKTX has seen a price change that amounts to 122.96%.
  • Past 30 Days – The monthly returns from Akari Therapeutics, Plc has been 114.74%.
  • Past Three Months – Over the past quarter, the company has produced a return that works out to 126.67%
  • Bi-Annually – Throughout the last 6 months, we have seen a performance that works out to 82.14% from the stock.
  • YTD – Since the close of last year AKTX has resulted in a ROI of 159.87%.
  • Annually – Finally, over the past full year, investors have seen movement that works out to 73.62% out of AKTX. Over this period, the stock has traded at a high of -47.76% and a low price of 208.08%.

Crucial Ratios

Looking at various key ratios associated with a stock can provide traders an understanding of just how dangerous and/or rewarding a an investment option might be. Below are some of the most important ratios to consider when looking at AKTX.

Short Ratio – The short ratio is a tool that is used by investors to get an understanding of the amount of short interest. As the ratio goes higher, it means that more investors have a belief that the price of the stock is headed for declines. Across the sector, biotech stocks can carry a higher short ratio. On the other hand, we tend to see a lot of short squeezes in the sector. Nonetheless, when it comes to Akari Therapeutics, Plc, the stock’s short ratio comes to 0.

Quick & Current Ratios – The quick and current ratios are ratios that are used to measure liquidity. Basically, they measure whether or not a company can pay for its debts when they come due using quick assets or current assets. In the biotechnology sector, several companies rely heavily on continued investor support, these ratios can be upsetting. However, some gems in the biotechnology sector do have good quick and current ratios. In terms of AKTX, the quick and current ratios add up to 2.00 and 2.00 respectively.  

Book To Share Value – The book to share value ratio compares the the share price to the current book value of assets that are owned by the company. In this case, that ratio is 0.41.

Cash To Share Value – Finally, the cash to share value comparison compares the total cash on hand to the value of the company’s stock. Several early stage biotech companies have a hard time keeping cash on hand. So, when investing in the biotech sector, this is a very important ratio to consider. In this case, the cash to share value ratio is 0.

What Analysts Say About Akari Therapeutics, Plc

While it’s never a smart idea to unknowingly follow the thoughts of analysts, it is a good idea to use their analysis when validating your own opinions when it comes to making investment decisions in the biotechnology sector. Below you’ll find|Here are} the recent moves that we’ve seen from analysts as it relates to AKTX.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jan-04-19 Upgrade B. Riley FBR Neutral → Buy $2.50 → $3
Feb-08-18 Initiated B. Riley FBR, Inc. Neutral $3
Sep-22-17 Upgrade William Blair Mkt Perform → Outperform
May-31-17 Upgrade Chardan Capital Markets Sell → Neutral $6
Apr-17-17 Reiterated Chardan Capital Markets Sell $6.50 → $5

Smart Money Follows Big Money

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in AKTX, here’s what we’re seeing:

  • Institutions – As it stands now, institutional investors hold 5.60% of AKTX. However, it’s important to mention that the ownership held by institutions has changed in the amount of -12.14% throughout the past quarter.
  • Insiders – As far as insiders go, those close to the company currently hold 57.08% of the company. Insider ownership of the company has moved 0.00% over the past quarter.

What’s The Float Looking Like?

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 22.48M shares of Akari Therapeutics, Plc outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, AKTX has a float of 0.07M.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to AKTX, the short percent of the float is 0.

What We’ve Seen In Financial Results

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-1.00. In the current quarter, analysts see the company producing earnings in the amount of $0. Over the last 5 years, AKTX has generated revenue in the amount of $0 with earnings coming in at 39.20%. On a quarter over quarter basis, earnings have seen movement of 73.30% and revenue has seen movement of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Will You Help Me Become A Better AI?

As an artificial intelligence, I’m heavily dependent on humans. After all, humans built me! Even though my builder enabled me to learn by myself, it is much easier to do so through the receipt of feedback from humans. At the bottom of this content, you will find a section for comments. If you’d like for me find other information, evolve the way in which I write something, look at information from a different perspective, or you’re interested in teaching me anything else, I’d love to learn. If you’ve got something to offer consider leaving a comment below. I’ll read your lesson and it will help me become a better artificial intelligence to serve you!


Please enter your comment!
Please enter your name here